About MIT TLO     MIT Community     For Industry     Resources  
 
 
 

Licenses for RNAi Patents

MIT is the licensing agent for the siRNA patents commonly referred to as the “Tuschl Patents” in the research reagent field.  There are a variety of ways to get access to these patents for research uses, and these are described more fully below .  Tuschl I is co-owned by MIT, The Whitehead Institute for Biomedical Research, The University of Massachusetts and Max Planck Gesellschaft zur Foerderung der Wissenschaften e.V.  Tuschl II is owned by the Gesellschaft zur Foerderung der Wissenschaften e.V.  MIT and the other co-owners have agreed that not to assert the Tuschl Patents against companies that sell or use DNA vectors which induce production of siRNA endogenously, provided that such vectors are only used for research purposes, and provided that the RNA that mediates RNA interference is not isolated from the transformed cells.  View a copy of this non-assert.

Tuschl I

"THE USES OF 21-23 SEQUENCE-SPECIFIC MEDIATORS OF DOUBLE-STRANDED RNA INTERFERENCE AS A TOOL TO STUDY GENE FUNCTION AND AS A GENE-SPECIFIC THERAPEUTIC," by David P. Bartel, Phillip A. Sharp, Thomas Tuschl and Phillip D. Zamore

  1. United States Patents and Applications

    United States of America Serial No. 09/821832, Filed March 30, 2001
    United States of America Serial No. 10/255568, Filed September 26, 2002
    "RNA Sequence-Specific Mediators Of RNA Interference" by David P. Bartel, Phillip A. Sharp, Thomas Tuschl and Phillip D. Zamore

  2. International (non-U.S.) Patents and Applications
    Australia Serial No. 2001249622, Filed March 30, 2001
    Brazil Serial No. PI0107536-5, Filed March 30, 2001
    Canada Serial No. 2404890, Filed March 30, 2001
    European Patent Convention Serial No. 01922870.9, Filed March 30, 2001
    Israel Serial No. 151928, Filed March 30, 2001
    Japan Serial No. 2001-573036, Filed March 30, 2001
    Korea (south) Serial No. 20027012832, Filed March 30, 2001
    New Zealand Serial No. 522045, Filed March 30, 2001
    Patent Convention Treaty Serial No. US01/10188, Filed March 30, 2001
    "RNA Sequence Specific Mediators Of RNA Interference"

Tuschl II

"RNA Interference Mediating Small RNA Molecules" by  Thomas Tuschl, Sayda Elbashir and Winfried Lendeckel

  1. United States Patents and Applications

    United States of America Serial No. 10/433050, Filed November 29,  2001
    United States of America Serial No. 10/832248, Filed November 29,  2001
    United States of America Serial No. 10/832257, Filed November 29,  2001
    United States of America Serial No. 10/832432, Filed November 29,  2001
    "RNA Interference Mediating Small RNA Molecules"

  2. International (non-U.S.) Patents and Applications

    Australia Serial No. 2002235744, Filed November 29, 2001
    Brazil Serial No. PI0115814-7, Filed November 29, 2001
    Canada Serial No. 2429814, Filed November 29, 2001
    China Serial No. 01820900.9, Filed November 29, 2001
    Czech Republic Serial No. PV2003-1839, Filed November 29, 2001
    European Patent Convention Serial No. 1407044, Filed November 29, 2001
    Hungary Serial No. P0302557, Filed November 29, 2001
    India Serial No. 612/KOLNP/03, Filed November 29, 2001
    Israel Serial No. 155991, Filed November 29, 2001
    Japan Serial No. 2002-546670, Filed November 29, 2001
    Korea (south) Serial No. 2003-7006978, Filed November 29, 2001
    Mexico Serial No. 2003004836, Filed November 29, 2001
    New Zealand Serial No. 525888, Filed November 29, 2001
    Norway Serial No. 20032464, Filed November 29, 2001
    Patent Convention Treaty Serial No. EP01/13968, Filed November 29, 2001
    Poland Serial No. P365784, Filed November 29, 2001
    Russian Federation Serial No. 2003119457, Filed November 29, 2001
    Singapore Serial No. 200302756-2, Filed November 29, 2001
    South Africa Patent No. 2003/3929, Issued September 29, 2004

Access to the Tuschl I and Tuschl II patents for research purposes is available via several routes:

  1. Purchase oligos from a licensed supplier.
    If you purchase your oligos from a licensed supplier, and use them for research purposes, you need no further license from MIT. The licensed suppliers are: [Applied Biosystems (formerly Ambion), Sigma, Qiagen and Dharmacon].
  2. Vector Based Delivery of siRNA
    MIT and the other co-owners of these patents have agreed not to assert the Tuschl Patents against companies that sell or use DNA vectors which induce production of siRNA endogenously, provided that such vectors are only used for research purposes, and provided that the RNA that mediates RNA interference is not isolated from the transformed cells (link to non-assert)
  3. Internal Use Licenses
    Companies that wish to use the siRNA oligos, but don’t wish to purchase them from a licensed supplier may get an internal use license from MIT which allows the company to make their own siRNA, or have it made on their behalf.
  4. Functional Genomics Service License
    Companies that wish to provide functional genomics services to third parties, using siRNA, may do so by either (1) purchasing all oligos used in the service from one of the licensed suppliers (Applied Biosystems (formerly Ambion), Sigma, Qiagen and Dharmacon), or (2) by entering into a Service Provider Agreement.
  5. Therapeutic Rights
    Therapeutic Rights have been exclusively licensed.

Contact Information:
Aaron Schwartz
Technology Licensing Officer
(617) 253-6966

adschwar@mit.edu